Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
Active, not recruiting · NCT06631079 · Registry updated 2026-01-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors | Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-08 | NCT06631079 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| NEC Bio B.V | 2 |
| NEC Bio Therapeutics | 2 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Charité | Berlin | Germany | 2 |
| CHUS Santiago de Compostela | Santiago de Compostela | Spain | 2 |
| Comprehensive Cancer Center | Munich | Germany | 1 |
| Fundacion Jimenez Diaz | Madrid | Spain | 7 |
| Institut Catala d'Oncologia | Barcelona | Spain | 4 |
| National Cancer Center | Vilnius | Lithuania | 1 |
| NCT | Heidelberg | Germany | 1 |
| Vall d'Hebron | Barcelona | Spain | 5 |